Globus Medical director granted 15,000 stock options
Globus Medical director Ann D. Rhoads received a new stock option award.
Rhea-AI Filing Summary
Globus Medical director Ann D. Rhoads received a new stock option award. On January 21, 2026, she was granted options to purchase 15,000 shares of Globus Medical Class A common stock at an exercise price of $94.15 per share. The options were granted at a price of $0 for the derivative itself and are held directly. They will vest on January 1, 2027 and are scheduled to expire on January 21, 2036, giving her a long-term incentive tied to the company’s share performance.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 15,000 shares
Grant/Award
1 txn
Insider
RHOADS ANN D
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy Class A Common Stock) | 15,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy Class A Common Stock) — 15,000 contracts (Direct)
Footnotes (1)
- F1. These options were granted on January 21, 2026, and will vest on January 1, 2027.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Globus Medical (GMED) disclose in this Form 4?
The filing shows that director Ann D. Rhoads received a grant of stock options on January 21, 2026 covering 15,000 shares of Globus Medical Class A common stock.
How many Globus Medical stock options were granted to Ann D. Rhoads?
Ann D. Rhoads was granted 15,000 stock options, each representing the right to buy one share of Globus Medical Class A common stock.
What is the exercise price and term of the new GMED stock options?
The options have an exercise price of $94.15 per share and are scheduled to expire on January 21, 2036, giving a long-dated option term.
When do Ann D. Rhoads’s Globus Medical options vest?
According to the footnote, these options were granted on January 21, 2026 and will vest on January 1, 2027.
Are these Globus Medical options held directly or indirectly by Ann D. Rhoads?
The Form 4 lists ownership as Direct (D), indicating Ann D. Rhoads holds these 15,000 options directly rather than through an intermediary entity.
AI-generated analysis. How Rhea-AI works. Not financial advice.